NEW YORK, NY--(Marketwire - January 12, 2012) -
Daxor Corporation (NYSE Amex: DXR
), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Mayo Clinic in Scottsdale, Arizona. This agreement will provide the Mayo Clinic with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis. Published studies using the BVA-100 have shown that blood volume measurement is important in treating heart failure, critical care patients in intensive care units, and in diagnosing the true status of complex anemias and syncope (fainting).
The Mayo Clinic in Rochester, Minnesota, a 1,302-bed general medical and surgical facility, ranked as the #2 hospital for cardiac and heart surgery in the annual U.S. News and World Report Survey of U.S. Hospitals for 2011-2012. The Mayo Clinic purchased its BVA-100 Blood Volume Analyzer in 2000.
The Mayo Clinic in Arizona is a five-story, 240-exam room outpatient clinic offering outpatient surgery, laboratory, diagnostic testing, imaging and pharmacy services. The clinic has 244 licensed hospital beds with 18 operating rooms, an urgent care/emergency room, a transplant center and a full-service clinical laboratory. It also offers diagnostic imaging and non-invasive heart tests and lung testing services, and operates a Level II emergency department serving patients from the surrounding area, as well as from all 50 states and several foreign countries.
Dr. Joseph Feldshuh, the President of Daxor, stated that the mission of Daxor is to make the Blood Volume Analyzer a standard of care in the treatment of critical conditions such as heart failure and intensive care unit medicine. At the present time hundreds of thousands of critically ill patients are being treated on the basis of clinical guesses, which have been demonstrated on the basis of published studies, to be inaccurate. The decision, for example, to give or withhold a transfusion to a patient should be based on precise measurements which are available by actually measuring a patient's blood volume.
Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.